Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients.

Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients. Radiol Oncol. 2024 09 01; 58(3):348-356.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Agents
Everolimus
Female
Humans
Liver Neoplasms
Male
Middle Aged
Neuroendocrine Tumors
Octreotide
Organometallic Compounds
Positron Emission Tomography Computed Tomography
Radiopharmaceuticals
Receptors, Somatostatin
Retrospective Studies
Treatment Outcome

authors with profiles

Christine Schmid-Tannwald